{"id":"clobetasol-propionate-cream","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypertrichosis"},{"rate":null,"effect":"Acneiform eruptions"},{"rate":null,"effect":"Systemic absorption and HPA axis suppression (with prolonged use)"}]},"_chembl":null,"_dailymed":{"setId":"d40ea303-9eba-4750-955d-6bb005882fb5","title":"CLOBETASOL PROPIONATE CREAM USP, 0.05% CLOBETASOL PROPIONATE CREAM USP, 0.05% (CLOBETASOL PROPIONATE USP, 0.05%) CREAM [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of local inflammatory responses. This results in rapid reduction of erythema, pruritus, and other signs of skin inflammation in dermatological conditions.","oneSentence":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:51.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses"},{"name":"Psoriasis"},{"name":"Lichen planus"},{"name":"Eczema"},{"name":"Dermatitis"}]},"trialDetails":[{"nctId":"NCT04563923","phase":"PHASE2","title":"Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2020-10-10","conditions":"Bullous Pemphigoid","enrollment":15},{"nctId":"NCT03926299","phase":"NA","title":"Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Prof. Dr. Volker Viereck","startDate":"2019-07-15","conditions":"Chronic Skin Disease, Vulvar Lichen Sclerosus","enrollment":66},{"nctId":"NCT02360202","phase":"PHASE4","title":"Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2015-02-17","conditions":"Bullous Pemphigoid","enrollment":30},{"nctId":"NCT05010421","phase":"PHASE3","title":"Laser vs Clobetasol for Lichen Sclerosus","status":"COMPLETED","sponsor":"Ruhr University of Bochum","startDate":"2021-11-02","conditions":"Lichen Sclerosus","enrollment":246},{"nctId":"NCT07240389","phase":"NA","title":"Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.","status":"NOT_YET_RECRUITING","sponsor":"Milosz Pietrus","startDate":"2025-12-01","conditions":"Vulvar Lichen Sclerosus","enrollment":45},{"nctId":"NCT06856590","phase":"NA","title":"ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction","status":"COMPLETED","sponsor":"Gazi University","startDate":"2025-02-20","conditions":"Hand-Foot Skin Reaction (HFSR)","enrollment":150},{"nctId":"NCT05706870","phase":"PHASE2","title":"Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis","status":"COMPLETED","sponsor":"GEN İlaç ve Sağlık Ürünleri A.Ş.","startDate":"2022-12-07","conditions":"Psoriasis","enrollment":190},{"nctId":"NCT02376049","phase":"PHASE1","title":"A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-02","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT03179605","phase":"PHASE2","title":"Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06","status":"TERMINATED","sponsor":"Primus Pharmaceuticals","startDate":"2017-05-02","conditions":"Psoriasis","enrollment":22},{"nctId":"NCT04220554","phase":"NA","title":"Improvement of Psoriasis Patients' Adherence to Topical Drugs","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2020-06-19","conditions":"Psoriasis Vulgaris","enrollment":103},{"nctId":"NCT06042647","phase":"PHASE4","title":"Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-07-13","conditions":"Psoriasis Vulgaris","enrollment":10},{"nctId":"NCT05428202","phase":"PHASE1","title":"Phase I Study of GN-037 Cream for Psoriasis","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2022-03-28","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT03926377","phase":"PHASE4","title":"Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2019-04-01","conditions":"Osteoporosis, Bullous Pemphigoid","enrollment":50},{"nctId":"NCT04719962","phase":"NA","title":"Direct Diagnosis of Disseminated Lyme Borreliosis.","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-07-07","conditions":"Lyme Disease","enrollment":10},{"nctId":"NCT05228483","phase":"NA","title":"Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen Sclerosus","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2021-11-23","conditions":"Vulva Lichen Sclerosus","enrollment":134},{"nctId":"NCT04719559","phase":"NA","title":"Fractional Laser and Steroid Ointment to Improve the Old Scar After Thyroidectomy","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2018-03-20","conditions":"Thyroid; Wound, Steroid Acne","enrollment":10},{"nctId":"NCT03878771","phase":"PHASE1","title":"PRF in Management of Chronic Multiple Oral Ulcers","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-03-13","conditions":"Oral Ulcer Due to Pemphius Vularis, Oral Ulcer Due to Benign Mucous Membrane Pemphioid, Oral Ulcer Due to Steven Johnson's Syndrome","enrollment":804},{"nctId":"NCT03983460","phase":"NA","title":"Dupilumab Impact on Skin Resident Memory T Cells","status":"UNKNOWN","sponsor":"Association pour la Recherche Clinique et Immunologique","startDate":"2020-03-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36},{"nctId":"NCT03535233","phase":"PHASE4","title":"Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT02131324","phase":"PHASE2","title":"DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2014-05-08","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT02445807","phase":"PHASE3","title":"A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2015-12","conditions":"Chronic Stable Plaque Psoriasis","enrollment":265},{"nctId":"NCT02635204","phase":"PHASE3","title":"A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2015-12","conditions":"Psoriasis","enrollment":267},{"nctId":"NCT02936492","phase":"PHASE1","title":"BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-10-24","conditions":"Psoriasis","enrollment":32},{"nctId":"NCT01381445","phase":"PHASE1","title":"A Study Assessing GW870086's Potential to Cause Skin Thinning","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-14","conditions":"Dermatitis, Atopic","enrollment":20},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36},{"nctId":"NCT02940002","phase":"PHASE1","title":"BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-10-12","conditions":"Psoriasis","enrollment":23},{"nctId":"NCT00470392","phase":"NA","title":"Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2007-05","conditions":"Psoriasis","enrollment":9},{"nctId":"NCT02744378","phase":"PHASE2","title":"Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Peradeniya","startDate":"2014-06","conditions":"Oral Lichen Planus","enrollment":68},{"nctId":"NCT00757874","phase":"PHASE2","title":"Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Deana Funaro","startDate":"2006-04","conditions":"Vulvar Lichen Sclerosus","enrollment":56},{"nctId":"NCT01987076","phase":"NA","title":"Comparison Between Corticosteroid and Topical Steroids in the DRESS","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-10","conditions":"Drug Rash With Eosinophilia and Systemic Symptoms","enrollment":112},{"nctId":"NCT00393263","phase":"PHASE2","title":"Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Center for Vulvovaginal Disorders","startDate":"2006-10","conditions":"Lichen Sclerosus","enrollment":38},{"nctId":"NCT01453686","phase":"PHASE3","title":"A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2002-08","conditions":"Alopecia Areata","enrollment":41}],"_emaApprovals":[],"_faersSignals":[{"count":51,"reaction":"DRUG INEFFECTIVE"},{"count":19,"reaction":"PRURITUS"},{"count":13,"reaction":"OFF LABEL USE"},{"count":12,"reaction":"BURNING SENSATION"},{"count":12,"reaction":"ERYTHEMA"},{"count":11,"reaction":"DRY SKIN"},{"count":11,"reaction":"RASH"},{"count":9,"reaction":"PRODUCT USE ISSUE"},{"count":8,"reaction":"APPLICATION SITE PAIN"},{"count":7,"reaction":"HEADACHE"}],"_approvalHistory":[{"date":"20200828","type":"ORIG","sponsor":"ENCUBE","applicationNumber":"ANDA212982"}],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dermovate","Clobex® Spray"],"phase":"marketed","status":"active","brandName":"Clobetasol propionate cream","genericName":"Clobetasol propionate cream","companyName":"LEO Pharma","companyId":"leo-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Psoriasis, Lichen planus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}